Weiss Asset Management LP Takes Position in BioCryst Pharmaceuticals, Inc. $BCRX

Posted by Brian Himes on Jul 28th, 2026

Weiss Asset Management LP purchased a new stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 82,100 shares of the biotechnology company’s stock, valued at approximately $782,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Larson Financial Group LLC lifted its position in BioCryst Pharmaceuticals by 1,188.0% during the 4th quarter. Larson Financial Group LLC now owns 3,542 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 3,267 shares during the period. Focus Partners Wealth acquired a new stake in shares of BioCryst Pharmaceuticals during the 3rd quarter worth approximately $77,000. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of BioCryst Pharmaceuticals by 26.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,231 shares of the biotechnology company’s stock worth $80,000 after buying an additional 2,115 shares during the last quarter. Elevation Point Wealth Partners LLC bought a new stake in shares of BioCryst Pharmaceuticals during the third quarter worth approximately $81,000. Finally, Mercer Global Advisors Inc. ADV acquired a new position in BioCryst Pharmaceuticals in the third quarter valued at approximately $81,000. 85.88% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on BCRX. Wall Street Zen cut shares of BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 9th. HC Wainwright reissued a “buy” rating and issued a $32.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday, June 30th. Citizens Jmp raised their price target on BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the stock a “market outperform” rating in a research report on Thursday, May 7th. Royal Bank Of Canada raised their price target on BioCryst Pharmaceuticals from $13.00 to $14.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 7th. Finally, JPMorgan Chase & Co. assumed coverage on BioCryst Pharmaceuticals in a research note on Monday, July 13th. They set a “neutral” rating and a $12.00 price objective for the company. Eight research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $20.80.

Check Out Our Latest Report on BCRX

BioCryst Pharmaceuticals Stock Up 2.6%

Shares of BCRX stock opened at $9.58 on Tuesday. BioCryst Pharmaceuticals, Inc. has a 12-month low of $6.00 and a 12-month high of $11.22. The firm has a market capitalization of $2.43 billion, a price-to-earnings ratio of -5.38 and a beta of 0.55. The firm has a fifty day moving average of $9.23 and a 200-day moving average of $8.59.

BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report) last released its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported ($2.98) EPS for the quarter, missing analysts’ consensus estimates of $0.06 by ($3.04). The firm had revenue of $156.41 million during the quarter, compared to the consensus estimate of $151.12 million. BioCryst Pharmaceuticals had a negative net margin of 51.71% and a negative return on equity of 76.36%. BioCryst Pharmaceuticals’s quarterly revenue was up 7.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.20 EPS. Research analysts expect that BioCryst Pharmaceuticals, Inc. will post -2.58 earnings per share for the current year.

BioCryst Pharmaceuticals Company Profile

(Free Report)

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.